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1. Introduction 
Aneurysmal subarachnoid hemorrhage (SAH) is a neurosurgical emergency that results 
from the rupture of an aneurysm in the subarachnoid space (see figure 1). SAH carries a 
high mortality rate, estimated at 45%; additionally, a significant amount of patients are left 
with impaired neurologic function [1]. The critical care management of SAH requires an 
appreciation of both neurologic and general critical care principles; it is best thought of as a 
systemic multi-organ disease.  
1.1. Epidemiology & morbidity  
The clinical burden of aneurysmal SAH is immense. Case fatality approaches 50%, and 
approximately 1 in 8 patients die prior to reaching the hospital [2]. Of those that survive, 
nearly 50% will have significant functional impairment [3].  Aneurysmal SAH accounts for 
approximately 85% of all non-traumatic SAH. Approximately 30,000 Americans are affected 
annually [1]. The incidence of aneurysmal SAH ranges from 6-21/100,000 patient years [4].  
1.2. Risk factors  
Risk factors for development of aneurysmal SAH can be categorized as modifiable and non-
modifiable. Modifiable risk factors include cocaine abuse, hypertension, and cigarette 
smoking [4]. It is estimated that cigarette use increases the risk of aneurysmal SAH by a 
factor of 3.7-3.9 [5]. Non-modifiable risk factors include sex, ethnicity, family history, and 
collagen-vascular diseases. The female:male ratio for aneurysmal SAH is approximately 2:1 
[6]. The incidence of aneurysmal SAH is higher amongst people of Finnish and Japanese 
descent; and the incidence of aneurysmal SAH is almost three times greater in Finland than 
other parts of the world [4]. The incidence of intracranial aneurysms is higher in patients 
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with collagen vascular diseases, such as Marfan’s Syndrome, Ehlor’s-Danlos Disease, 
Neurofibromatosis Type 1, and Autosomal dominant polycystic kidney disease [7].  
 
Borrowed with permission: Ellegala D, Day A. (2005) Ruptured Cerebral Aneurysms. New England Journal of 
Medicine. 352: 121-124 
Figure 1. The arterial blood supply to the brain is located primarily in the subarachnoid space (Panel B). 
Aneurysm formation occurs in the subarachnoid space (Panel C), which must be surgically accessed to 
provide definitive treatment of the aneurysm (Panel E). 
2. Diagnosis 
2.1. Clinical presentation 
The classic presentation of a patient with aneurysmal SAH is thunderclap headache, often 
described as the “worst headache of my life.” It is generally abrupt in onset and reaches 
maximal intensity instantly. However, this classic description is seen in only 50% of patients 
presenting with aneurysmal SAH [8]. Conversely, in those patients prospectively screened 
for acute severe headache, only 6-17% were demonstrated to have SAH [9,10]. Common 
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features at presentation can include seizure, loss of consciousness, and nausea and emesis 
preceding onset of headache [9]. The concept of ‘sentinel headache’ remains controversial; it 
is thought to be related to changes in the wall of the aneurysm versus a microbleed. A 
sentinel headache generally presents as a severe headache lasting greater than an hour, but 
diagnostic evaluation does not lead to the confirmation of SAH. These patients are at higher 
risk for early re-bleeding and aneurysmal SAH. The estimated relative odds ratio is 2.5-3.8 
increase in early re-bleeding in patients who present initially with a sentinel headache [11]. 
2.2. Physical examination 
Patients with aneurysmal SAH can have a variety of examination findings at presentation. 
These may range from a headache without focal neurologic deficits to being comatose. Most 
commonly, patients may have a depressed level of consciousness or confusional state. 
Cranial nerve palsies are also frequently seen as a direct result of an aneurysm; though 
cranial nerve 6 palsy may be a sign of elevated intracranial pressure.  Focal weakness is also 
noted in a small percentage of patients. Fundoscopic examination may reveal subhyaloid 
hemorrhages and papilledema. Clinical correlation with outcome is best defined by the 
Hunt & Hess grading scale (see Table 1) [12].  
2.3. Neuro-imaging  
In addition to clinical presentation, the vast majority of SAH is diagnosed with correlating 
neuro-imaging. Non-contrast Head CT is the preferred modality of choice for the initial 
evaluation. Retrospective analysis has reported a sensitivity of 91-100% [13]. The sensitivity 
of non-contrast head CT diminishes as time elapses from the time of onset. It is best during 
the first 24 hours and diminishes to 85% at 5 days and subsequently to 50% at 1 week [14]. 
False negatives may occur in patients with anemia and is dependent upon the experience of 
the reading neuroradiologist [15]. MRI offers a higher sensitivity to detect SAH in patients 
presenting outside of first 48 hours after onset; however MRI is not readily available at most 
institutions and some patients may not be suitable for MRI. The FLAIR (fluid attenuated 
inversion recovery) and GRE (gradient echo) sequences are the most reliable method for 
detection of SAH in MRI [16].  
Detection of aneurysms is best with catheter digital subtraction angiography, which remains 
the gold standard. In our practice, we perform a CT angiogram at admission, which carries a 
85-98% sensitivity in comparison to catheter angiography. On average, 10-20% of patients 
with non-traumatic SAH will have a non-diagnostic catheter angiogram [17]. Practice varies 
in terms of repeat angiography; our current practice is to repeat an angiogram between 10-
14 days.   
2.4. Lumbar puncture  
Cerebro-spinal fluid (CSF) analysis remains an essential aid in diagnosis in CT-Negative 
patients presenting with acute onset of severe thunderclap headache. Lumbar puncture 
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should ideally occur 6-12 hours after onset of symptoms to optimize sensitivity. Lysis of red 
cells and the formation of oxyhemoglobin and bilirubin produce xanthochromia, ideally 
detected visually by inspection and confirmed by spectophotometry. CSF can remain 
positive for up to 7 days following ictus [18].  
2.5. Classification 
Various classifications exist for SAH. These range from clinical grading systems to 
radiographic scales. The most commonly used scales are Hunt & Hess, and World 
Federation of Neurological Surgeons (WFNS) scales [19]. (See Table 1) 
 
Grade Hunt & Hess WFNS Survival 
1 Asymptomatic or minimal headache and 
slight nuchal rigidity 
GCS 15, no motor 
deficit 
70% 
2 Moderate to severe headache, nuchal 
rigidity, no neurology deficit other than 
cranial nerve palsy 
GCS 13-14, no motor 
deficit 
60% 
3 Drowsy, confusion, or mild focal deficit GCS 13-14, motor 
deficit 
50% 
4 Stupor, moderate to severe hemiparesis, 
possibly early decerebrate rigidity and 
vegetative disturbances 
GCS 7-12 with or 
without motor deficit
20% 
5 Deep coma, decerebrate rigidity, moribund 
appearance 
GCS 3-6 with or 
without motor deficit
10% 
Adapted from - Rosen et al. (2005) Subarachnoid Hemorrhage Grading Scales: A Systemic Review. Neurocrit Care. 2: 
110-118. 
Table 1. Clinical grading scales for aneurysmal SAH and percent survival correlated with Hunt & Hess.  
2.6. Differential diagnosis 
Not all non-traumatic SAH is necessarily aneurysmal; however all non-traumatic SAH is 
treated as aneurysmal unless it is evident from clinical history or radiographic imaging that 
it is low risk. Most commonly, angiographic negative SAH is secondary to 
perimesencephalic hemorrhages. These compromise 10% of all SAH and two-thirds of non-
traumatic SAH with negative angiograms. Blood is generally located ventral to brainstem in 
the prepontine and perimesencephalic cisterns. Generally, intraventricular hemorrhage 
(IVH) is rare. The average patient with perimesencephalic SAH is above the age of 50 and 
has less severe deficits. Rebleeding and vasospasm are infrequent in these patients [17].   
Most SAH is in fact traumatic; however a collaborating history is not always obtained. Of 
those patients that have non-traumatic, non-aneurysmal SAH, intradural dissection is a 
concern; this is typically of the vertebral artery. Rupture of arteriovenous malformations 
(AVM) can occasionally extravasate blood into the cisternal space. Additionally, 
Arteriovenous Dural fistulas, mycotic aneurysms, pituitary apoplexy, and moya moya 
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disease should remain on the differential, though there is generally additional history to 
suggest these. Cerebral vasculitis should remain a diagnosis of exclusion in patients with 
unexplained subarachnoid hemorrhage. The pattern of SAH on neuroimaging directs 
further work up. A non-classic pattern of cisternal hemorrhage suggests perimesencephalic 
or AVM related SAH. Blood present in the cortical sulci is generally thought to be traumatic, 
though can be associated with AVM rupture and vasculitis [17].  
3. Management 
The critical care management of aneurysmal SAH can be thought of as three distinct phases: 
Immediate management (prior to securing the culprit aneurysm), entrapment of the 
aneurysm, and post entrapment management. Technical aspects and surgical management 
in entrapment of the aneurysm are described elsewhere [20, 21]. In this chapter we focus 
primarily on critical care management of aneurysmal SAH and potential complications.  
3.1. Immediate management  
The major risk of fatality following aneurysmal SAH occurs within the first 24 hours and is 
related to the risk of re-rupture of the aneurysm. Rebleeding occurs primarily within the 
first 8 hours and is present in 9-17% of patients within the first 72 hours [22]. Rebleeding 
carries a significant mortality rate – up to 50% [17]. Therefore, prevention of rebleeding is 
key in management.  
Management in the 1980’s of aneurysmal SAH incorporated the use of antifibrinolytics to 
diminish the risk of rebleeding. In these patients, antifibrinolytics were continued for weeks 
at a time. However, this practice was subsequently abandoned when further studies 
suggested that though rebleeding was diminished, complications of delayed cerebral 
ischemia, primarily vasospasm, increased and there was little difference in outcomes [23].  
Recently, there has been renewed interest in the use of short-term (12-48 hours) 
antifibrinolytic therapy. Because complications of delayed cerebral ischemia and vasospasm 
generally occur after day 3, and the greatest risk of re-rupture is within the first 48 hours, a 
short duration of antifibrinolytic therapy may improve outcomes. A significant reduction in 
the rate of rebleeding, 11% to 2.5% has been observed in patients treated with an early short 
course of the antifibrinolytic tranexamic acid [24]. However, no study to date has been 
powered adequately to assess clinical outcome benefit with early short duration 
antifibrinolytic therapy. One study, however, has shown an increase in the rate of DVT’s 
associated with the use antifibrinolytic therapy [25]. The Neurocritical Care Society’s 
consensus statement on management of SAH recommends considering an initial early short 
course of an antifibrinolytic with early definitive treatment of the aneurysm [26]. Our current 
practice is to utilize antifibrinolytic therapy as early surgery/intervention is being arranged.  
No clear hemodynamic goals have been defined in patients with aneurysmal SAH prior to 
entrapment of the aneurysm. Practice varies from center to center with the general 
consensus that elevated blood pressure raises the concern for early rebleeding. Early studies 
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reported that induced hypertension and hypervolemia were associated with aneurysmal 
rebleeding and hemorrhagic transformation; however, further studies have failed to 
demonstrate this link. The consensus statement from the Neurocritical Care Society 
observed that modest hypertension (SBP <160mmHg, MAP < 110mmHg) was not associated 
with rebleeding [26].  
Hydrocephalus is a frequent complication of aneurysmal SAH and is seen in 15-30% of SAH 
patients. The clinical impact of hydrocephalus is variable. Patients may be asymptomatic to 
obtunded. CSF diversion thru ventriculostomy generally resolves hydrocephalus and often 
times, a marked improvement is noted in level of consciousness [1]. Our clinical practice is 
to place ventriculostomies in all Hunt and Hess Grade 3 or higher aneurysmal SAH.  
3.2. Securing the aneurysm 
The key treatment of aneurysmal SAH is securing or trapping the aneurysm, thereby 
reducing the probability of rebleeding. Patients who have early surgery, within the first 72 
hours, had an overall mortality rate equivalent to patients with delayed surgery (days 11-
32); however, those with early surgery had significantly better clinical recovery [27]. The 
general consensus is that aneurysms should be secured within the first 24-48 hours 
following rupture The technical aspects and surgical management in entrapment of the 
aneurysm are beyond the scope of this chapter and are described elsewhere [20, 21] 
3.3. Post entrapment management 
The majority of the length of stay for aneurysmal SAH patients occurs post-surgical 
trapping. It is during this time that patients remain at high risk for neurologic deterioration 
secondary to vasospasm, delayed cerebral ischemia, seizures, hyponatremia, and other 
complications.  
Management during this period relies on close  serial neurologic assessment, and prompt 
management of complications.  
Traditionally, patients with aneurysmal SAH have been treated with triple H therapy – 
consisting of hypervolemia, hemodilution, and hypertension. As our understanding of 
aneurysmal SAH advances, this strategy has changed significantly.  
3.3.1. Volume status  
Monitoring volume status in critically ill patients can be challenging, but remains essential 
to optimizing medical care. Patients with aneurysmal SAH frequently develop hypovolemia 
and hyponatremia as a consequence of cerebral salt wasting syndrome. Retrospective 
studies demonstrate an increase in ischemia and worse outcomes in patients with 
hypovolemia [28].  
Fluid balance does not necessarily reflect intravascular volume [29]. Some have advocated 
CVP while others rely on PAC to optimize volume status. CVP appears to be unreliable as 
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an indicator of volume status and the use of routine PAC is cumbersome and the risks 
outweigh the benefits [30, 31]. Few have shifted to beside ultrasound and distensibility of 
the inferior vena cava [32]. However, none of these measures of intravascular volume  have 
proven reliable. A combination of both invasive and non-invasive monitoring in conjunction 
with other clinical indicators of volume status provide the best guide for targeting therapy 
[26].  
Induced hypervolemia has been investigated in two prospective randomized trials – no 
benefit was found in vasospasm or clinical outcome [33, 34]. Therefore, our clinical practice 
is to target euvolemia. Preferred volume of choice is isotonic crystalloid [26]. 
Mineralocorticoid supplementation with fludrocortisone has demonstrated the reduction in 
need of intravenous fluids needed to maintain euvolemia [35]. 
3.3.2. Prophylactic measures  
3.3.2.1. Nimodipine 
Calcium antagonists have been studied as agents to reduce the incidence of vasospasm 
associated with aneurysmal SAH. To date, nimodipine, a member of the dihydropyridine 
family of calcium antagonists, has been the only medication shown to have significant 
improvement in clinical outcome in patients with aneurysmal SAH [37]. Typical dosing is 
60mg every 4 hours orally and is continued for 21 days. Treatment with nimodipine led to a 
relative risk reduction of 24% for poor outcome [37].  
3.3.2.2. Magnesium 
Magnesium has attracted study in patients with aneurysmal SAH as it is a non-competitive 
calcium antagonist with important vascular and potential neuroprotective effects [38]. 
Dosing and optimal magnesium levels are not well agreed upon; however, 
hypomagnesemia is related to a worse outcome. Studies have yielded conflicting results. 
The largest trial to date did not demonstrate any outcome difference between those targeted 
with hypermagnesemia [39]. A second Phase III study, MASH-II, is currently underway. 
Our current practice is to target Magnesium levels between 2.0 and 3.0 mg/dL, and to avoid 
hypomagnesemia pending results of MASH-II [26].  
3.3.2.3. Statins  
The many beneficial effects of statins have made them targets for consideration as 
prophylactic agents in aneurysmal SAH patients. Clinical trials have, however, not 
demonstrated a consistent beneficial effect. A meta-analysis suggested that there may be a 
reduction in delayed cerebral ischemic (DCI) with statins, however, patients in these studies 
had a higher rate of DCI than typically reported elsewhere [40]. Another meta-analysis of 4 
randomized trials showed no benefit with statin prophylaxis in Trans-Cranial Doppler 
(TCD) detected vasospasm, functional outcome, or mortality [41].  
Though no studies have directly addressed continuing or withdrawing statins in patients 
with aneurysmal SAH, there is data from patients with ischemic stroke and myocardial 
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infarction that suggests acute statin withdrawal can worsen outcome [42, 43]. Until further 
data is available from clinical trials, the consensus is not to initiate treatment with a statin; 
however, one should be continued if it has been prescribed prior to aneurysmal SAH [26].  
3.3.2.4. Seizure 
Seizures may occur with aneurysmal rupture; patients may also develop chronic epilepsy 
following aneurysmal SAH. The incidence of seizures during the acute phase of aneurysmal 
SAH varies: studies estimate a range between 8-30% [1]. Other estimates are more 
conservative ranging between 1-7% at the time of rupture [21]. Continuous EEG monitoring 
in patients with poor grade SAH demonstrated a 10-20% prevalence of non-convulsive 
seizures [44]. Risk factors for developing seizures include age > 65 years, thick subarachnoid 
clot, rupture of a middle cerebral artery aneurysm, and intraparenchymal hemorrhage [45].  
Prophylactic treatment of seizures has been commonplace; however, recent studies have 
investigated the benefit and risks involved [26]. Prophylactic use with phenytoin has been 
demonstrated to lead to worse outcomes [46]. Shorter duration prophylaxis has been 
advocated and a 3-7 day course of prophylaxis is general practice. Other anti-epileptic 
agents have been investigated and levetiracetam has been shown to be equally efficacious in 
reducing early seizures as well as improved functional recovery in comparison to those 
patients treated with phenytoin [47]. The current recommendation is to consider using 
short-term (3-7 days) of agents other than phenytoin, such as levetiracetam, for seizure 
prophylaxis. For patients with poor grade SAH with unexplained neurologic deterioration, 
continuous EEG monitoring is recommended [26].  
3.3.2.5. DVT  
Aneurysmal SAH induces a prothrombotic condition that can lead to an increase in deep 
venous thrombosis (DVT), and pulmonary embolism (PE). Incidence of DVT varies between 
1.5-1.8%, with poor grade SAH having a higher incidence [48].  
Conventionally, sequential compression devices (SCDs), unfractionated heparin, and low-
molecular weight heparin have been used. One meta-analysis showed all were similarly 
effective in preventing DVT, but there was a trend towards higher rates of hemorrhage 
(intracerebral and non-cerebral) in those with low molecular weight heparins [49]. Timing of 
initiation is controversial, but generally, it is felt safe to assume pharmacologic prophylaxis 
after 24 hours from onset. Similarly, pharmacologic prophylaxis should be held 24 hours 
before and after intracranial procedures [26].  
3.3.2.6. Glycemic control 
Hyperglycemia is often diagnosed in patients with SAH; numerous studies have associated 
admission hyperglycemia with poor clinical grade and outcome [50]. The optimal range of 
glycemic control in patients with aneurysmal SAH is unknown. One study has shown 
improved outcomes with tight glycemic control: 80-140mg/dL, achieved thru insulin 
infusion [51]. However, when tightened to 80-110mg/dL, outcomes were worse secondary to 
episodic hypoglycemia and vasospasm [52]. Extrapolating data from other critically ill 
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populations suggests that patients on insulin infusions are more likely to develop 
hypoglycemia [53]. Microdialysis studies have shown cerebral glucose levels to decrease, 
even without systemic hypoglycemia [54]. Based on the available data, hypoglycemia 
should be avoided and system glycemic control should target < 200mg/dL [26].  
3.3.2.7. Pyrexia 
Fever is very common in patients with SAH; studies report between 41-72% of patients with 
aneurysmal SAH will have fever. Fever is independently associated with poor outcome in 
retrospective studies of SAH [55]. As such, aggressive work up of fever is obligatory to look 
for underlying infection, drug reaction, or thrombosis. No clinical trial has prospectively 
examined induced normothermia and outcome; however, given the increased morbidity 
with fever, it is prudent to manage pyrexia [56]. Strategies to decrease fever include 
medications such acetaminophen, and NSAIDs. More aggressive devices include cooling 
blankets, and intravascular temperature modulation devices. The deleterious effects of 
aggressive cooling can include shivering and should be monitored for and aggressively 
combated [26].  
3.3.2.8. Anemia 
Anemia develops in over 50% of patients with Aneurysmal SAH and Hemoglobin 
concentrations decrease to less than 11g/dL in more than 80% of patients [57]. Because under 
normal circumstances when cerebral oxygen delivery demands metabolic demand, these 
levels are well tolerated. However, patients with aneurysmal SAH are at risk for developing 
vasospasm and DCI; their metabolic needs may not be met.  
The optimal target hemoglobin in this patient population is not known. Retrospective 
studies have demonstrated that higher hemoglobin concentrations were associated with 
good functional outcomes [58]. PET imaging studies show an improvement in delivery of 
cerebral oxygen when hemoglobin is improved from 8g/dL to 10g/dL thru red cell 
transfusion [59].  However, evidence from broader based critically ill patients suggest that 
there is lower mortality in patients with a restrictive transfusion strategy [60].  
Current guidelines suggest minimizing blood loss from blood drawing, as well as 
consideration of packed red cells to maintain hemoglobin concentrations between 8-
10g/dL. Patients with DCI are the most likely to benefit from this higher transfusion 
strategy [26].  
3.3.3. Complications of aneurysmal subarachnoid hemorrhage 
Direct neurologic complications include cerebral vasospasm and delayed cerebral ischemia. 
Acute hydrocephalus and a diminished threshold for seizures have been discussed 
previously. Systemic complications of aneurysmal SAH include cardiac, pulmonary, and 
electrolyte abnormalities (see Figure 2). Fever, anemia, hyperglycemia are also common and 
have been discussed previously.   
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Adapted from – Coppadoro A, Citerio G (2011) Subarachnoid Hemorrhage: An Update for the Intensivist. Minerva 
Anestesiologica. 77: 74-84.  
Figure 2. Cardio-pulmonary complications of aneurysmal SAH are related to the surge in 
catecholamines.  
3.3.3.1. Cardiac complications 
Cardiac complications following aneurysmal SAH are frequent and range from 
hemodynamic instability to cardiac arrhythmias to myocardial injury and heart failure. 
Given the high prevalence of cardiac complications, all patients with aneurysmal SAH 
should have an ECG, cardiac enzymes, and echocardiogram on admission.  
ECG abnormalities most commonly seen following aneurysmal SAH are ST segment 
alterations, prominent U waves, QT-prolongation and other conduction abnormalities. 
Older age, hyperglycemia, and longer length of state are associated with atrial fibrillation 
and atrial flutter [61].  
Troponin I is elevated on admission in 20-34% of patients with aneurysmal SAH. Studies 
have suggested that elevated troponin I is an independent risk factor for severe disability 
and death at hospital discharge. Higher grade SAH, IVH, and loss of consciousness at ictus 
have all been associated with elevated troponin I [62].  
Acute heart failure and myocardial injury are most commonly seen in higher-grade SAH 
patients; the most severe form is neurogenic stunned myocardium. The surge of 
catecholamine release associated with SAH is thought to be responsible for neurogenic 
stunned myocardium, however the exact mechanism remains poorly understood. The classic 
 
The Critical Care Management of Aneurysmal Subarachnoid Hemorrhage 393 
pathologic findings are myocardial contraction band necrosis. Presentation includes transient 
lactic acidosis, cardiogenic shock, pulmonary edema, widespread T wave inversions, and 
reversible wall motion abnormalities [63]. One prospective study revealed a 18% (35% in 
Grade III-V) prevalence of wall motion abnormalities on echocardiogram in patients with 
aneurysmal SAH [64]. Takotsubo cardiac myopathy, also known as apical ballooning 
syndrome, is a subset of stunned myocardial injury seen most commonly in post-
menopausal women and is associated with pulmonary edema and prolonged mechanical 
ventilation [65].  
3.3.3.2. Pulmonary complications  
Pulmonary complications are frequent (22%) and include impairment in gas exchange, 
pneumonia (20%), pulmonary edema (14%), and pulmonary embolism (0.3) [61]. These 
represent common manifestations of pulmonary disease in general critical care patients. 
Patients with aneurysmal SAH are however prone to develop aspiration pneumonias given 
a higher frequency of impaired consciousness. Thus, vigilant aggressive pulmonary toilet 
and aspiration precautions are important.  
Neurogenic pulmonary edema (NPE) is associated with various neurologic insults, 
including SAH, seizures, and traumatic brain injury. It is thought to be a result of massive 
sympathetic discharge and catecholamine release at ictus, resulting in vasoconstriction and 
an increase in MAP with subsequent shift of intravascular volume to a lower-resistance 
pulmonary bed. The role of cardiac dysfunction in association aneurysmal SAH also 
contributes to pulmonary edema in these patients. NPE is associated with poor outcomes 
and is seen in patients with higher grade SAH. These patients are challenging to manage. 
Maintaining euvolemia in SAH patients decreases the risk of vasospasm; and it is well 
accepted that hypovolemia increases risk of vasospasm.  Thus, cautious use of diuretic 
therapy is indicated when oxygenation and/or hemodynamic instability as a result of heart 
failure develop [66].  
3.3.3.3. Hyponatremia 
Hyponatremia is prevalent in up to 57% of patients with aneurysmal SAH [67]. It is the most 
commonly encountered electrolyte abnormality in NeuroScience ICU’s. Severe 
hyponatremia is associated with seizures, and worsening of cerebral edema. In patients with 
aneurysmal SAH, hyponatremia is associated with increasing risk of vasospasm, likely 
secondary to its association with hypovolemia [68]. 
Hyponatremia in the setting of aneurysmal SAH can either be caused by Cerebral salt 
wasting (CSW) or the Syndrome of Inappropriate Antidiuresis (also known as Syndrome of 
Inappropriate Antidiuretic Hormone – SIADH). The proportion of patients with CSW 
versus SIADH as the cause of hyponatremia in aneurysmal SAH varies depending on the 
study, but CSW is more likely. Distinguishing CSW and SIADH is of clinical importance as 
the management is different, and can adversely affect outcomes in patients with aneurysmal 
SAH [68].  
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CSW is a result of natriuresis: loss of sodium resulting in loss of free water leading to 
hyponatremia; it is thus a hypovolemic hyponatremia. SIADH results from inappropriate 
anti-diuresis and is thus a euvolemic hyponatremia. Distinguishing the two is often difficult. 
Generally, patients with SIADH have decreased urine output in comparison to CSW. Urine 
osmolality is generally lower to normal in patients with CSW and high in patients with 
SIADH. Urine sodium levels are elevated in both. However, these are not always reliable; 
volume status, if determined reliably, is likely the most accurate method for distinguishing 
CSW from SIADH [69]. 
The mechanism of CSW is not completely understood. It is thought to result from 
interference of sympathetic input to the kidney and from elevated circulating natriuretic 
factors seen after cerebral injury [68].  
CSW in patients with aneurysmal SAH are treated with Na supplementation and restoration 
of volume. This is achieved thru the use of salt tablets and hypertonic saline solutions. 
Mineralocorticoid supplementation is useful to increase Na and volume; typically, 
fludrocortisone is used. Therapy is targeted to maintain Na >135 [68].  
More recently, the vasopressin receptor antagonist conivaptan has become available. It may 
cause an increase in diuresis and lead to a negative fluid balance. Though originally 
intended for the treatment of SIADH, it has been used cautiously in the hyponatremic 
patient with aneurysmal SAH [70].   
3.3.3.4. Systemic Inflammatory Response (SIRS) 
The catecholamine release associated with aneurysmal subarachnoid hemorrhage along 
with pro-inflammatory cytokines can lead to SIRS. The presence of SIRS criteria on 
admission (body temperature, heart rate, respiratory rate, and white blood cell count) in 
patients with aneurysmal SAH is a significant independent predictor of vasospasm and 
hydrocephalus. It is also associated with a higher mortality and morbidity rate [71].  
3.3.3.5. Vasospasm and delayed cerebral ischemia 
Vasospasm refers to the narrowing and vasoconstriction of cerebral arteries following 
aneurysmal SAH; it is prevalent in 70% of patients with aneurysmal SAH. Delayed cerebral 
ischemia refers specifically to the clinical and neurologic deterioration, often related to 
severe cerebral vasospasm, and occurs in 20-30% of patients with aneurysmal SAH.  
The best predictor of cerebral vasospasm is thickness of cisternal clot and intraventricular 
hemorrhage, as seen on CT scan [72]. The Fisher and modified Fisher grading scales are 
used to predict expected risk of vasospasm (see table 2) [73]. 
Cerebral vasospasm typically starts after post-bleed day 3 and can extend thru 21 days, 
though most cases resolve within 14 days. The generation of microemboli, cortical 
spreading ischemia, and microcirculatory spasm are thought to add to DCI [74, 75]. (See 
Figure 3) 
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Grade Fisher Scale 
Percent with 
Symptomatic 
Vasospasm 
Modified Fisher Scale 
Percent with 
Symptomatic 
Vasospasm 
1 Focal Thin 21% 
Focal or Diffuse Thin 
SAH, no IVH 
24% 
2 Diffuse Thin SAH 25% 
Focal or Diffuse Thin 
SAH, with IVH 
33% 
3 Thick SAH Present 37% 
Thick SAH Present, no 
IVH 
33% 
4 
Focal or Diffuse thin 
SAH with significant 
ICH or IVH 
31% 
Thick SAH Present, with 
IVH 
40% 
Adapted from – Frontera et al. (2006) Prediction of Symptomatic Vasospasm After Subarachnoid Hemorrhage: The 
Modified Fisher Scale. Neurosurgery. 58: 21-26 
Table 2. Fisher and Modified Fisher grading scales for aneurysmal SAH with percentage of patients 
within grade with symptomatic vasospasm.  
 
 
 
 
Borrowed with permission: MacDonald R et al. (2007) Cerebral Vasospasm After Subarachnoid Hemorrhage: The 
Emerging Revolution. Nature  Clinical Practice Neurology. 3: 256-263.  
Figure 3. Complications and risk against time in aneurysmal SAH 
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Cerebral vasospasm is the highest contributing factor to morbidity in patients with 
aneurysmal SAH. Cerebral vasospasm may have evolved as a protective measure to prevent 
re-rupture of a cerebral aneurysm; however, its diffuse cerebral effects are deleterious and 
add significant morbidity to aneurysmal SAH. Vasospasm is thought to occur secondary to 
blood product degradation in the subarachnoid space. Deoxy-hemoglobin and oxy-
hemoglobin decrease perivascular nitric oxide and increase endothelin-1 respectively. The 
net result is a pathologic prolongation of calcium in smooth muscle, leading to an increase in 
spasm, apoptosis, and vascular remodeling [75].  
Monitoring for vasospasm is of great value in the management of aneurysmal SAH. TCD, 
CT Angiography with perfusion imaging, and conventional digital subtraction angiography 
are options for monitoring for cerebral vasospasm.  
The advantages of TCD are its noninvasive low risk profile; however it’s sensitivity is 
variable and dependent on the skill of the ultrasonographer. Many patients have poor trans-
cranial windows, making monitoring with TCD’s difficult, if not impossible. Mean flow 
velocities are typically utilized for detection of vasospasm. Using a mean fellow velocities 
less than 120cm/s has a 94% negative predictive value for cerebral vasospasm. Mean flow 
velocities greater than 130cm/s have been proposed as the threshold for mild-moderate 
vasospasm; this carries a 73% sensitivity and 100% specificity for detecting vasospasm. 
Mean flow velocities greater than 200cm/s reliably predict moderate to severe angiographic 
vasospasm. The Lindegaard ratio compares intracranial MCA mean flow velocity to 
extracranial ICA mean flow velocity; the advantage of a ratio is to distinguish hyperemic 
states from vasospasm. Ratios greater 4 are suggestive of vasospasm; a ratio greater than 6 
reliably predicts cerebral vasospasm [76].  
CT angiography has a 87-95% percent sensitivity for angiographic vasospasm, but carries a 
high negative predictive value approaching 99%. However, CT angiography and perfusion 
are cumbersome and may pose additional risk to the patient secondary to iodinated 
contrast. CT angiography with perfusion may be a surveillance option for patients who have 
poor TCD windows [26]. 
Non-interventional strategies to combat cerebral vasospasm include the traditional triple H 
model. Augmenting MAP has been utilized to decrease DCI associated with cerebral 
vasospasm [74]. Our practice utilizes MAP goals between 110-140 to treat cerebral 
vasospasm.  
Few centers have utilized intrathecal calcium antagonists. Some have utilized intrathecal 
nicardapine with success in decreasing flow velocities as measured by TCD’s [77]. 
Multicenter randomized trials utilizing have yet to be completed demonstrating efficacy. 
The trigger for intervention varies between centers. Many centers choose an aggressive 
intervention including endovascular delivery of local intra-arterial verapamil (and other 
calcium antagonists) that have an immediate effect with resulting local vasodilatation. 
Specific management of interventional management of vasospasm associated with 
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aneurysmal SAH are described in more detail elsewhere [78]. The current gold standard for 
refractory cerebral vasospasm includes angioplasty in conjunction with intra-arterial 
delivery of calcium channel antagonists [26].  
4. System based practice  
Most patients with aneurysmal SAH are treated at small volume centers seeing fewer than 
18 cases per year. Mortality is substantially greater at small volume centers compared to 
larger high volume referral centers [79]. Moreover, studies suggest that the utilization of a 
dedicated neurocritical care team is associated with improvement in hospital discharge 
disposition in patients with aneurysmal SAH [80].  
5. Conclusion   
Aneurysmal SAH is a complex critical illness with multisystem complications that requires 
the close attention of a dedicated neurocritical care team. Mortality and morbidity are high; 
the likelihood of a good outcome depends on presentation grade and careful and diligent 
management of complications.  
Author details 
Vishal N. Patel 
Emory University School of Medicine,Marcus Stroke & NeuroScience Critical Care Center,  
Grady Memorial Hospital, Atlanta, GA 
Owen B. Samuels 
Emory University School of Medicine, Division of Neurointensive Care, Emory University Hospital, 
Neuroscience Critical Care and Stroke Units, Atlanta, GA 
6. References 
[1] Wendell L, Levin J. (2010) How Should Aneurysmal Subarachnoid Hemorrhage Be 
Managed. In: Deutschman C, Neligan P, editors. Evidence-Based Practice of Critical 
Care. Philadelphia: Saunders. pp 414-421. 
[2] van Gijn et al. (2007) Subarachnoid Haemorrhage. Lancet. 369: 306-318. 
[3] Suarez et al (2006) Aneurysmal Subarachnoid Hemorrhage. N Engl J Med. 354:  
387-396. 
[4] Linn et al. (1996) Incidence of Subarachnoid Hemorrhage: Role of Region, Year, and 
Rate of Compute Tomography: A Meta-Analysis. Stroke. 27: 625-629.  
[5] Bell B, Symon L. (1979) Smoking and Subarachnoid Haemorrhage. BMJ. 1: 577-578. 
[6] Kongable G et al. (1996) Gender-Related Differences in Aneurysmal Subarachnoid 
Hemorrhage. J Neurosurg. 84: 43-48.  
[7] Schievink. (1997) Intracranial Aneurysms. N Engl J Med. 336: 28-40.  
 
Aneurysm 398 
[8] Linn et al. (1998) Headache Characteristics in Subarachnoid Hemorrhage and Benign 
Thunderclap Headache. J Neuro Neurosurg Psychiatry. 65: 791-793.  
[9] Linn et al (1994) Prospective Study of Sentinel Headache in Aneurysmal Subarachnoid 
Haemorrhage. Lancet. 344: 590-593.  
[10] Morgenstern et al. (1998) Worst Headache and Subarachnoid Hemorrhage: Prospective, 
Modern Computed Tomography and Spinal Fluid Analysis. Annals of Emergency 
Medicine. 32: 297-304.  
[11] Beck J et al. (2006) Sentinel Headache and Risk of Rebleeding After Aneurysmal 
Subarachnoid Hemorrhage. Stroke. 37: 2733-2737.  
[12] Hunt E, Hess R (1968). Surgical Risk as Related to Time of Intervention in the Repair of 
Intracranial Aneurysms. J Neurosurg. 28: 14-20.  
[13] Byyny et al. (2008) Sensitivity of Noncontrast Cranial Computed Tomography for the 
Emergency Department Diagnosis of Subarachnoid Hemorrhage. Annals of Emergency 
Medicine. 51: 697-703.  
[14] van Gijn et al (1982) The Time Course of Aneurysmal Haemorrhage on Computed 
Tomograms. Neuroradiology. 23: 153-156.  
[15] Edlow et al. (2000) Avoiding the Pitfalls in the Diagnosis of Subarachnoid Hemorrhage. 
N Engl J Med. 342: 29-36.  
[16] Mitchell P et al. (2001) Detection of Subarachnoid Hemorrhage with Magnetic 
Resonance Imaging. J Neurol Neurosurg Psychiatry. 70: 205-211. 
[17] van Gijn et al. (2001). Subarachnoid Haemorrhage: Diagnosis, Causes, and 
Management. Brain. 124: 249-278. 
[18] Irani, D (2008) Cerebrospinal Fluid in Clinical Practice. Philadelphia: Sauders. 317p. 
[19] Rosen et al. (2005) Subarachnoid Hemorrhage Grading Scales: A Systemic Review. 
Neurocrit Care. 2: 110-118.  
[20] Lawton M (2011) Seven Aneurysms. New York: Thieme Medical Publishing, 224p. 
[21] Molyneux et al. (2005) International Subarachnoid Aneurysm Trial (ISAT) of 
Neurosurgical Clipping Versus Endovascular Coiling in 2143 Patients with Ruptured 
Intracranial Aneurysms: A Randomized Comparison of Effects on Survival, 
Dependency, Seizures, Rebleeding, Subgroups, and Aneurysm Occlusion. Lancet. 366: 
809-817. 
[22] Starke et al. (2011) Rebleeding After Aneurysmal Subarachnoid Hemorrhage. Neurocrit 
Care. 15: 241-246.  
[23] Roos et al (2003) Antifibrinolytic Therapy for Aneurysmal Subarachnoid Hemorrhage. 
Cochrane Database of Systemic Reviews. 2: CD001245 
[24] Hillman et al. (2002) Immediate Administration of Tranexamic Acid and Reduced 
Incidence of Early Rebleeding After Aneurysmal Subarachnoid Hemorrhage: A 
Prospective Randomized Study. J Neurosurg. 97: 771-778.  
[25] Starke et al. (2008) Impact of a Protocol for Acute Antifibrinolytic Therapy on 
Aneurysm Rebleeding after Subarachnoid Hemorrhage. Stroke. 39: 2617-2621.  
 
The Critical Care Management of Aneurysmal Subarachnoid Hemorrhage 399 
[26] Diringer et al. (2011) Critical Care Management of Patients Following Aneurysmal 
Subarachnoid Hemorrhage: Recommendations from the Neurocritical Care Society’s 
Multidisciplinary Consensus Conference. Neurocrit Care. 15: 211-240.  
[27] Haley E, Kassell N, and Torner J (1992) The International Cooperative Study on the 
Timing of Aneurysm Surgery: The North American Experience. Stroke. 23: 205-214.  
[28] Wijdecks et al. (1985) Volume Depletion and Natriuresis in Patients with Ruptured 
Intracranial Aneurysms: Is Fluid Restriction Harmful? Ann Neurol. 17: 137-140.  
[29] Hoff et al. (2008) Fluid Balance and Blood Volume Measurement After Aneurysmal 
Subarachnoid Hemorrhage. Neurocrit Care. 8: 391-397.  
[30] Hoff et al (2009) Blood Volume Measurement to Guide Fluid Therapy After 
Aneurysmal Subarachnoid Hemorrhage: A Prospective Controlled Study. Stroke. 40: 
2575-2577. 
[31] Mutoh et al. (2009) Performance of Bedside Transpulmonary Thermodilution 
Monitoring for Goal Directed Hemodynamic Management after Subarachnoid 
Hemorrhage. Stroke. 40: 2368-2374. 
[32] Moretti R, Pizzi B (2010) Inferior Vena Cava Distensibility as a Predictor of Fluid 
Responsiveness in Patients with Subarachnoid Hemorrhage. Neurorcit Care. 13: 3-9.  
[33] Lennihan et al. (2000) Effect of Hypervolemic Therapy on Cerebral Blood Flow After 
Subarachnoid Hemorrhage: A Randomized Controlled Trial. Stroke. 31: 381-338.  
[34] Egge et al. (20001) Prophylactic Hyperdynamic Postoperative Fluid Therapy After 
Aneurysmal Subarachnoid Hemorrhage: A Clinical, Prospective, Randomized 
Controlled Study. Neurosurgery. 49: 593-605.  
[35] Woo M, Kale-Pradhan P (1997) Fludrocortisone in the Treatment of Subarachnoid 
Hemorrhage Induced Hyponatremia. Ann Pharmacother. 31: 637-639.  
[36] Allen et al. (1983) Cerebral Arterial Spasm – A Controlled Trial of Nimodipine in 
Patients with Subarachnoid Hemorrhage.  N Engl J Med. 308: 619-624 
[37] Felgin et al. (1998) Calcium Antagonists in Patients with Aneurysmal Subarachnoid 
Hemorrhage: A Systematic Review. Neurology. 50: 876-883.  
[38] Taccone F (2010) Vasodilatation and Neuroprotection: The Magnesium Saga in 
Subarachnoid Hemorrhage. Crit Care Med. 38: 1382-1384.  
[39] Wong et al. (2010) Intravenous Magnesium Sulphate for Aneurysmal Subarachnoid 
Hemorrhage (IMASH): A Randomized, Double-Blinded, Placebo-Controlled, 
Multicenter Phase III Trial. Stroke. 41: 921-926.  
[40] Kramer A, Fletcher J (2009) Statins in the Management of Patients with Aneurysmal 
Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis. Neurocrit Care. 
12: 285-296.  
[41] Vergouwen et al. (2009) Effect of Statin Treatment on Vasospasm, Delayed Cerebral 
Ischemia, and Functional Outcome in Patients with Aneurysmal Subarachnoid 
Hemorrhage: A Systematic Review and Meta-Analysis Update. Stroke. 41: e47-52.  
[42] Blanco et al. (2007) Statin Treatment Withdrawal in Ischemic Stroke: A Controlled 
Randomized Study. Neurology. 69: 904-910.  
 
Aneurysm 400 
[43] Heeschen et al. (2002) Withdrawal of Statins Increases Event Rates in Patients with 
Acute Coronary Syndromes. Circulation. 105: 1446-1452.  
[44] Little et al (2007) Nonconvulsive Status Epilepticus in Patients Suffering Spontaneous 
Subarachnoid Hemorrhage. J Neurosurg. 106: 805-811. 
[45] Choi et al. (2009) Seizures and Epilepsy Following Aneurysmal Subarachnoid 
Hemorrhage: Incidence and Risk Factors. J Korean Neurosurg Soc. 46: 93-98.  
[46] Naidech et al. (2005) Phenytoin Exposure is Associated with Functional and Cognitive 
Disability after Subarachnoid Hemorrhage. Stroke. 36: 583-587. 
[47] Szaflarski et al (20010). Prospective, Randomized, Single-Blinded Comparative Trial of 
Intravenous Levetiracetam Versus Phenytoin for Seizure Prophylaxis. Neurocrit Care. 
12: 165-172.  
[48] Ray W et al. (2009) Incidence of Deep Venous Thrombosis After Subarachnoid 
Hemorrhage. J Neurosurg. 110: 1010-1014.  
[49] Collen J et al. (2008) Prevention of Venous Thromboembolism in Neurosurgery: A 
Meta-Analysis. Chest. 134: 237-249.  
[50] Kruyt N et al. (2009) Hyperglycemia and clinical Outcome in Aneurysmal Subarachnoid 
Hemorrhage: A Meta-Analysis. Stroke. 40: e424-430. 
[51] Pasternk J et al. (2008) Hyperglycemia in Patients Undergoing Cerebral Aneurysm 
Surgery: Its Association with Long-Term Gross Neurologic and Neuropsychological 
Function. Mayo Clin Proc. 83: 406-417.  
[52] Naidech A et al. (2010) Moderate Hypoglycemia is Associated with Vasospasm, 
Cerebral Infarction, and 3-Month Disability after Subarachnoid Hemorrhage. Neurocrit 
Care. 12: 181-187.  
[53] Finfer S et al. (2009) Intensive Versus Conventional Glucose Control in Critically Ill 
Patients. N Engl J Med. 360: 1283-1297.  
[54] Schlenk F et al. (2008) Insulin-Related Decrease in Cerebral Glucose Despite 
Normoglycemia in Aneurysmal Subarachnoid Hemorrhage. Crit Care. 12: R9.  
[55] Fernandez A et al. (2007) Fever after Subarachnoid Hemorrhage: Risk Factors and 
Impact on Outcome. Neurology. 68: 1013-1019.  
[56] Aiyagari V, Diringer, M. (2007) Fever Control and its Impact on Outcomes: What is the 
Evidence? J Neurol Sci. 261: 39-46.  
[57] Kramer A et al. (2009) Relationship Between Hemoglobin Concentrations and 
Outcomes Across Subgroups of Patients with Aneurysmal Subarachnoid Hemorrhage. 
Neurocrit Care. 10: 157-165.  
[58] Naidech A et al. (2007) Higher Hemoglobin is Associated with Improved Outcome after 
Subarachnoid Hemorrhage. Crit Care Med. 35: 2383-2389.  
[59] Dhar R et al. (2009) Red Blood Cell Transfusion Increases Cerebral Oxygen Delivery in 
Anemic Patients with Subarachnoid Hemorrhage. Stroke. 40: 3039-3044.  
[60] Hebert P et al. (1999) A Multicenter, Randomized, Controlled Clinical Trial of 
Transfusion Requirements in Critical Care. Transfusion Requirements in Critical Care 
Investigators, Canadian Critical Care Trials Group. N Engl J Med. 340: 409-417.  
 
The Critical Care Management of Aneurysmal Subarachnoid Hemorrhage 401 
[61] Wartenberg K, Mayer S. (2010) Medical Complications After Subarachnoid 
Hemorrhage. Neurosurg Clin N Am. 21: 325-338.  
[62] Naidech et al. (2005) Cardiac Troponin Elevation, Cardiovascular Morbidity, and 
Outcome After Subarachnoid Hemorrhage. Circulation. 112: 2851- 
[63] Mayer S et al. (1994) Cardiac Injury Associated with Neurogenic Pulmonary Edema 
Following Subarachnoid Hemorrhage. Neurology. 44: 815-820.  
[64] Kothavale A et al. (2006) Predictors of Left Ventricular Regional Wall Motion 
Abnormalities After Subarachnoid Hemorrhage. Neurocrit Care. 4: 199-205.  
[65] Lee V et al. (2006) Tako-Tsubo Cardiomyopathy in Aneurysmal Subarachnoid 
Hemorrhage: an Underappreciated Ventricular Dysfunction. J Neurosurg. 105: 264-270.  
[66] Friedman J et al. (2003) Pulmonary Complications of Aneurysmal Subarachnoid 
Hemorrhage. Neurosurgery. 52: 1025-1031. 
[67] Sherlock M et al. (2006) The Incidence and Pathophysiology of Hyponatremia After 
Subarachnoid Hemorrhage. Clin Endocrinol. 64: 250-254.  
[68] Yee et al. (2010) Cerebral Salt Wasting: Pathophysiology, Diagnosis, and Treatment. 
Neurosurg Clin N Am. 21: 339-352. 
[69] Palmer B. (2000) Hyponatraemia in a Neurosurgical Patient: Syndrome of Inappropriate 
Antidiuretic Hormone secretion versus Cerebral Salt Wasting. Nephrol Dial Transplant. 
15: 262-268.  
[70] Wright W et al. (2009) Conivaptan for Hyponatremia in the Neurocritical Care Unit. 
Neurocrit Care. 1: 6-13.  
[71] Yoshimoto et al. (2000) Acute Systemic Inflammatory Response Syndrome in 
Subarachnoid Hemorrhage. Stroke. 32: 1989-1993.  
[72] Classen et al. (2001) Effect of Cisternal and Ventricular Blood on Risk of Delayed 
Cerebral Ischemia After Subarachnoid Hemorrhage: the Fischer Scale revisited. Stroke. 
32: 2012-2020.  
[73] Frontera et al. (2006) Prediction of Symptomatic Vasospasm After Subarachnoid 
Hemorrhage: The Modified Fisher Scale. 58: 21-26 
[74] Lazaridis C, Naval N. (2010) Risk Factors and Medical Management of Vasospasm After 
Subarachnoid Hemorrhage. Neurosurg Clin N Am. 21: 353-364.  
[75] MacDonald R et al. (2007) Cerebral Vasospasm After Subarachnoid Hemorrhage: The 
Emerging Revolution. Nature Clinical Practice Neurology. 3: 256-263. 
[76] Marshall S et al. (2010) The Role of Transcranial Doppler Ultrasonography in the 
Diagnosis and Management of Vasospasm After Aneurysmal Subarachnoid 
Hemorrhage. Neurosurg Clin N Am. 21: 291-303.  
[77] Ehtisham A et al. (2009) Use of Intrathecal Nicardapine for Aneurysmal Subarachnoid 
Hemorrhage-Induced Vasospasm. South Med J. 102: 150-153. 
[78] McGuinness B, Gandhi D. (2010) Endovascular Management of Cerebral Vasospasm. 
Neurosurg Clin N Am. 21: 281-290.  
[79] Cowan et al. (2003) Outcomes After Cerebral Aneurysm Clip Occlusion in the United 
States: the Need for Evidence-Based Hospital Referral. J Neurosurg. 99: 947-952.  
 
Aneurysm 402 
[80] Samuels O et al. (2011) Impact of a Dedicated Neurocritical Care Team in Treating 
Patients with Aneurysmal Subarachnoid Hemorrhage. Neurocrit Care. 14: 334-340.  
